16064-09-8

Basic information

• Product Name: 6-chloro-3-methylquinazolin-4(3H)-one
• CAS NO: 16064-09-8
• Molecular Formula: C₉H₇ClN₂O
• Molecular Weight: 194.6177
• Mol File: 16064-09-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 346.7°C at 760 mmHg
• Flash Point: 163.4°C
• Density: 1.37g/cm³
• Vapor Pressure: 5.67E-05mmHg at 25°C
• Refractive Index: 1.642
• CAS DataBase Reference: 6-chloro-3-methylquinazolin-4(3H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-chloro-3-methylquinazolin-4(3H)-one(16064-09-8)
• EPA Substance Registry System: 6-chloro-3-methylquinazolin-4(3H)-one(16064-09-8)

Safety Data

• Hazardous Substances Data: 16064-09-8(Hazardous Substances Data)

Upstream product

• 123-39-7 N-Methylformamide 
• 635-21-2 5-chloroanthranilic acid 
• 26208-56-0 5-Chlor-N-formyl-anthranilsaeure 
• 74-89-5 methylamine 

Downstream Products

• 878745-39-2 tert-butyl 4-methyl-3-(3-methyl-4-oxo-3,4-dihydroquinazolin-6-ylamino)phenylcarbamate 
• 1361513-18-9 6-chloro-1-[2-phenyl-2-oxoethyl]-3-methyl-4-oxo-3,4-dihydroquinazolin-1-ium bromide 
• 1422175-70-9 C₂₇H₂₃FN₆O₄S 
• 878745-42-7 6-(5-amino-2-methylphenylamino)-3-methylquinazolin-4(3H)-one 
• 1422176-00-8 C₂₇H₁₉F₄N₅O₃ 
• 1422175-99-2 C₂₇H₁₉F₄N₅O₃ 

Relevant articles and documents

PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5- MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS

The present disclosure relates to compounds of the Formula (I): and pharmaceutically acceptable salts, as kinase modulators, compatible with the Type-II inhibition of kinases.

4-Quinazolinones: Synthesis and reduction of prostaglandin E2 production

We synthesized and evaluated the anti-inflammatory activity of a series of 4-quinazolinone derivatives. Two approaches were used to yield the title compounds. A first group of quinazolinone derivatives was obtained by the appropriate substituted anthranilates. A second group of quinazolinone compounds was prepared through the benzoxazin-4-ones intermediate. The pharmacological results reveal that the synthesized derivatives exhibit a significant anti-inflammatory effect in an experimental ocular inflammation model. In fact, all the tested compounds lowered the prostaglandin E2 (PGE2) production with respect to the control group (P 2 levels even more than the reference drug tolmetin and significantly lower protein concentration and polymorphonuclear leukocytes number compared to the control group (P 0.05). Therefore, these compounds may be useful to prevent ocular inflammatory reactions.